Search

Your search keyword '"Palmieri, Fabiano"' showing total 3 results
Start Over Author "Palmieri, Fabiano" Topic luts
3 results on '"Palmieri, Fabiano"'

1. Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis

Author

Cindolo, Luca, De Nunzio, Cosimo, Greco, Francesco, Destefanis, Paolo, Bergamaschi, Franco, Ferrari, Giovanni, Fasolis, Giuseppe, Palmieri, Fabiano, Divan, Claudio, Oriti, Rino, Ruggera, Lorenzo, Tubaro, Andrea, Dadone, Claudio, De Rienzo, Gaetano, Frattini, Antonio, Mirone, Vincenzo, Schips, Luigi, Cindolo, L., De Nunzio, C., Marchioni, M., Greco, F., Destefanis, P., Frea, B., Bergamaschi, F., Ricciardulli, S., Ferrari, G., Fasolis, G., Varvello, F., Palmieri, F., Voce, S., Divan, C., Malossini, G., Oriti, R., Tuccio, A., Ruggera, L., Tubaro, A., Chiodini, P., Dadone, C., De Rienzo, G., Ditonno, P., Campobasso, D., Mirone, V., Frattini, A., Schips, L., and Members of Green Laser Italian Group

Published
2017
Full Text
View/download PDF

2. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study)

Author

Morgia, Giuseppe, Vespasiani, Giuseppe, Pareo, Rosaria M., Voce, Salvatore, Madonia, Massimo, Carini, Marco, Ingrassia, Antonio, Terrone, Carlo, Gentile, Marcello, Carrino, Maurizio, Giannantoni, Antonella, Blefari, Franco, Arnone, Salvatore, Santelli, Giorgio, Russo, Giorgio I., Reale, Giulio, Di Mauro, Marina, Fedelini, Paolo, Pucci, Luigi, Veneziano, Pasquale, Santaniello, Francesco, Ginepri, Andrea, Bitelli, Marco, Valerio Beatrici, M., Polledro, Patrizio, La Rosa, Pasquale, Chiancone, Francesco, Giannella, Riccardo, Del Fabbro, Dario, Farullo, Giuseppe, Cocci, Andrea, Lanciotti, Michele, Solinas, Tatiana, Di Dio, Agata, Dal Pozzo, Claudio, Palmieri, Fabiano, Zaganelli, Stefano, and Lacetera, Vito

Subjects
Male, benign prostatic enlargement, LUTS, prostate, Serenoa repens, tadalafil, medicine.medical_specialty, Urology, 030232 urology & nephrology, Prostatic Hyperplasia, Group B, law.invention, Tadalafil, 03 medical and health sciences, Selenium, 0302 clinical medicine, Lycopene, Randomized controlled trial, Lower Urinary Tract Symptoms, law, Lower urinary tract symptoms, Serenoa, medicine, Clinical endpoint, 80 and over, Humans, Adverse effect, Benign prostatic enlargement, Prostate, Aged, Aged, 80 and over, business.industry, Plant Extracts, Middle Aged, Phosphodiesterase 5 Inhibitors, medicine.disease, Drug Combinations, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Tablets, Urological Agents, International Prostate Symptom Score, business, medicine.drug
Abstract

OBJECTIVE To compare in a randomised, open-label, non-inferiority clinical study, the efficacy and tolerability of Serenoa repens (SeR) + selenium (Se) + lycopene (Ly) (SeR-Se-Ly) therapy vs tadalafil 5 mg in men with lower urinary tract symptoms (LUTS). PATIENTS AND METHODS From May 2015 to January 2017, 427 patients were enrolled in 21 different centres (International Standard Randomised Controlled Trial Number Register [ISRCTN] 73316039). Inclusion criteria included: age between 50 and 80 years, International Prostate Symptom Score (IPSS) ≥12, maximum urinary flow rate (Qmax ) ≤ 15 mL/s, and post-void residual (PVR)

Published
2018

3. Standard vs. anatomical 180-W GreenLight laser photoselective vaporization of the prostate: a propensity score analysis.

Author

Cindolo, Luca, De Nunzio, Cosimo, Greco, Francesco, Destefanis, Paolo, Bergamaschi, Franco, Ferrari, Giovanni, Fasolis, Giuseppe, Palmieri, Fabiano, Divan, Claudio, Oriti, Rino, Ruggera, Lorenzo, Tubaro, Andrea, Dadone, Claudio, De Rienzo, Gaetano, Frattini, Antonio, Mirone, Vincenzo, Schips, Luigi, and Members of Green Laser Italian Group

Subjects
LASER surgery, VAPORIZATION, PROPENSITY score matching, PROSTATE-specific antigen, MEDICAL databases
Abstract

Purpose: To compare the efficacy, safety, Patient Global Impression of Improvement (PGI-I), and complications rates after 180-W GreenLight laser (180-W GL laser) standard and anatomical photoselective vaporization (sPVP and aPVP). Methods: Within a multi-institutional database, we identified patients who underwent sPVP or aPVP to relief BPH symptoms. IPSS, Q , and prostate-specific antigen (PSA) were measured at baseline and during the follow-up. PGI-I score as well as early and late complications were recorded at follow-up visits. Log-binomial and multivariable proportional odds regression models were fitted to estimate the effect of aPVP vs. sPVP on PGI-I as well as on early and late complication rates, before and after adjustment for propensity score. Results: 813 patients were included. Of those, the 50.4% underwent aPVP. Patients who underwent aPVP had larger prostate (64 vs. 55 mL, p < 0.001) and higher baseline PSA levels (3.1 vs. 2.5 ng/mL, p < 0.001). PGI-I score was signaled as very improved, improved, slightly improved, unchanged, or worsened in 55.5, 32.8, 8.3, 2.3, and 1.2% of the cases, respectively, with no differences according the technique used ( p = 0.420). Acute urinary retention occurred in 9.2 vs. 8.9% of patients after aPVP vs. sPVP ( p = 0.872). All models failed to find differences in: patients' satisfaction (OR 1.19, p = 0.256), early complications (RR 0.93, p = 0.387), early urge/incontinence symptoms (RR 0.97, p = 0.814), and late complications rates (RR 0.70, p = 0.053), after aPVP vs. sPVP. Conclusion: Our results showed similar functional results and complication rates after aPVP and sPVP. However, aPVP was used in larger prostates. Both techniques guarantee high patient's satisfaction. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results